Madrigal (MDGL) Q2 Revenue Soars 1,313%
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical firm focused on liver diseases, reported its second quarter 2025 earnings on August 5, 2025. The standout news in this release was an explosive surge in GAAP revenue to $212.8 million, sharply exceeding the consensus estimate of $162.03 million. This outperformance was driven by strong demand for Rezdiffra, the company’s leading MASH therapy, and rapid patient uptake since its April 2024 launch. Operating expenses also grew markedly, reflecting the company’s intensive investment in commercial rollout and research. Overall, the quarter showcased rapid commercial momentum, substantial market adoption, and strategic execution.
Source: Analyst estimates for the quarter provided by FactSet.
Madrigal Pharmaceuticals develops treatments for serious liver diseases, most notably metabolic dysfunction-associated steatohepatitis (MASH), a type of progressive fatty liver disease. Its business centers around its lead product, Rezdiffra (resmetirom), which became the first and only therapy approved for MASH by the U.S. Food and Drug Administration (FDA) in March 2024. The recent period was defined by scaling up commercial operations, expanding into additional patient groups, building out international strategy, and protecting its competitive edge in a rapidly evolving market for MASH treatments.
Source Fool.com
